Nabriva Announces Change In Record Date For Planned Rights Offering

VIENNA, Austria and KING OF PRUSSIA, Pa., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (Nabriva) (NASDAQ:NBRV), an Austrian stock corporation, announced today that it has changed the record date for its previously announced planned rights offering from November 22, 2016 to November 29, 2016. Holders of common shares on the new record date will be entitled to exercise non-transferable statutory pre-emptive rights to subscribe for new common shares to maintain their proportionate ownership interest in Nabriva in accordance with the relevant provisions of the Austrian Stock Corporation Act. In addition, holders of American Depositary Shares (ADSs) as of 5:00 pm (New York City time) on the new record date will also receive non-transferable subscription rights to purchase new common shares, in the form of new ADSs, to maintain their proportionate ownership interest.  Each ADS represents one tenth (1/10) of a common share. 

Nabriva expects to announce additional details about the planned rights offering in the near future.  Nabriva reserves the right to cancel or terminate the rights offering at any time.

The rights offering will be made by means of a prospectus. When available, copies of the prospectus relating to the rights offering may be obtained from Nabriva Therapeutics AG, attention Will Sargent, at 1000 Continental Drive, Suite 600 King of Prussia, PA 19406 or

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and has become effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Nabriva Therapeutics AG

Nabriva Therapeutics is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics.

If you liked this article you might like

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money